Letters to the Editor

Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuria

Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita
Department of Hematology and Oncology, Tokai University, Isehara
Department of Hematology, Endocrinology and Metabolism, Niigata University Medical and Dental Hospital, Niigata
Department of Cardiology and Hematology, Fukushima Medical University, Fukushima
Department of Hematology, Tokyo Medical University, Shinjuku-ku, Tokyo
Department of Internal Medicine, Hematology and Oncology, Masaryk University Hospital and Faculty of Medicine, Brno, Czech Republic
Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos and Institute of Clinical Medicine, Vilnius University, Vilnius
Novartis Institutes for BioMedical Research, Basel, Switzerland, Cambridge, USA, and Novartis Pharma KK, Toranomon Minato-ku, Tokyo
Novartis Institutes for BioMedical Research, Basel, Switzerland, Cambridge, USA, and Novartis Pharma KK, Toranomon Minato-ku, Tokyo
Novartis Institutes for BioMedical Research, Basel, Switzerland, Cambridge, USA, and Novartis Pharma KK, Toranomon Minato-ku, Tokyo
Novartis Institutes for BioMedical Research, Basel, Switzerland, Cambridge, USA, and Novartis Pharma KK, Toranomon Minato-ku, Tokyo
Novartis Institutes for BioMedical Research, Basel, Switzerland, Cambridge, USA, and Novartis Pharma KK, Toranomon Minato-ku, Tokyo
Novartis Institutes for BioMedical Research, Basel, Switzerland, Cambridge, USA, and Novartis Pharma KK, Toranomon Minato-ku, Tokyo
Novartis Institutes for BioMedical Research, Basel, Switzerland, Cambridge, USA, and Novartis Pharma KK, Toranomon Minato-ku, Tokyo
Novartis Institutes for BioMedical Research, Basel, Switzerland, Cambridge, USA, and Novartis Pharma KK, Toranomon Minato-ku, Tokyo
Novartis Institutes for BioMedical Research, Basel, Switzerland, Cambridge, USA, and Novartis Pharma KK, Toranomon Minato-ku, Tokyo
Novartis Institutes for BioMedical Research, Basel, Switzerland, Cambridge, USA, and Novartis Pharma KK, Toranomon Minato-ku, Tokyo
Novartis Institutes for BioMedical Research, Basel, Switzerland, Cambridge, USA, and Novartis Pharma KK, Toranomon Minato-ku, Tokyo
Novartis Institutes for BioMedical Research, Basel, Switzerland, Cambridge, USA, and Novartis Pharma KK, Toranomon Minato-ku, Tokyo
Novartis Institutes for BioMedical Research, Basel, Switzerland, Cambridge, USA, and Novartis Pharma KK, Toranomon Minato-ku, Tokyo
Novartis Institutes for BioMedical Research, Basel, Switzerland, Cambridge, USA, and Novartis Pharma KK, Toranomon Minato-ku, Tokyo
Novartis Institutes for BioMedical Research, Basel, Switzerland, Cambridge, USA, and Novartis Pharma KK, Toranomon Minato-ku, Tokyo
Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan; Sumitomo Hospital, Osaka
Haematologica Early view Mar 10, 2022 https://doi.org/10.3324/haematol.2020.265868